Skip to main content
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2004 Jun 11;18(4):237–239. doi: 10.1002/jcla.20029

β‐trace protein, a new marker of GFR, may predict the early prognostic stages of patients with type 2 diabetic nephropathy

Mami Kobata 1, Ayumi Shimizu 1, Hisaki Rinno 2, Chieko Hamada 1, Kunimi Maeda 1, Mitsumine Fukui 1, Kensuke Saito 1,3, Satoshi Horikoshi 1, Yasuhiko Tomino 1,
PMCID: PMC6807906  PMID: 15202116

Abstract

The relationship between serum levels of β‐trace protein (BTP) or serum creatinine (s‐Cr) and the prognostic stages of type 2 diabetic nephropathy was determined. Serum samples from 174 patients with type 2 diabetes were obtained from Juntendo University Hospital, Tokyo, and Juntendo Urayasu Hospital, Chiba, Japan. They were classified into four groups according to the Report of the Ministry of Health and Welfare of Japan (1991, p 251–256) as follows: Stage I (normoalbuminuric stage), Stage II (microalbuminuric stage), Stage IIIA (macroalbuminuric stage without renal dysfunction), Stage IIIB (macroalbuminuric stage with renal dysfunction), and Stage IV (renal failure stage). Among these patients, 68 were Stage I, 29 Stage II, 32 Stage IIIA, 17 Stage IIIB, and 28 Stage IV. Levels of serum BTP were measured using the nephelometric assay on a BNA II analyzer (Dade Behring Diagnostics, Marburg, Germany). The mean levels of serum BTP in Stage IIIA were significantly higher than those in Stage I or II (P<0.00001, P<0.002, respectively). However, the mean levels of s‐Cr in Stage IIIA were not significantly higher than that in Stage I or II. In conclusion, serum BTP was a good marker for the identification of early renal impairment in type 2 diabetes. J. Clin. Lab. Anal. 18:237–239, 2004. © 2004 Wiley‐Liss, Inc.

Keywords: serumβ‐trace protein, serum creatinine, glomerular filtration rate, type 2 diabetic nephropathy

REFERENCES

  • 1. Shimizu A, Kobata M, Io H, et al. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002;92:224–226. [DOI] [PubMed] [Google Scholar]
  • 2. Shimizu A, Satoshi Horikoshi, Hisaki R, Mami K, Kensuke S, Tomino Y. Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal 2003;17:164–167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Clausen J. Proteins in normal cerebrospinal fluid not found in serum. Proc Soc Exp Biol Med 1961;107:170–172. [DOI] [PubMed] [Google Scholar]
  • 4. Urade Y, Hayashi O. Prostaglandin D synthase: structure and function. Vitam Horm 2000;58:89–120. [DOI] [PubMed] [Google Scholar]
  • 5. Urade Y, Hayashi O. Prostaglandin D2 and sleep regulation. Biochim Biophys Acta 1999;1436:606–615. [DOI] [PubMed] [Google Scholar]
  • 6. Report of the Ministry of Health and Welfare of Japan (in Japanese) . Stage Classification of Diabetic Nephropathy. Tokyo: Ministry of Health and Welfare of Japan; 1991. p 251–256. [Google Scholar]
  • 7. Woitas RP, Stoffel‐Wagner B, Flommersfeld S, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000;46:712–715. [PubMed] [Google Scholar]
  • 8. Newman DJ, Thakkar H, Edwards RG, et al. Serum cyatatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312–318. [DOI] [PubMed] [Google Scholar]
  • 9. Tumani H, Nau R, Felgenhauer K. β‐treace protein in cerebrospinal fluid: a blood‐CSF barrier‐related evaluation in neurological diseases. Ann Neurol 1998;44:882–889. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES